caa a22 4500 445315830 CHVBK 20180317142646.0 cr unu---uuuuu 170323e20110801xx s 000 0 eng 10.1007/s10552-011-9787-7 doi (NATIONALLICENCE)springer-10.1007/s10552-011-9787-7 Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study [Elektronische Daten] [Song Yao, Cathee Till, Alan Kristal, Phyllis Goodman, Ann Hsing, Catherine Tangen, Elizabeth Platz, Frank Stanczyk, Juergen Reichardt, Li Tang, Marian Neuhouser, Regina Santella, William Figg, Douglas Price, Howard Parnes, Scott Lippman, Ian Thompson, Christine Ambrosone, Ashraful Hoque] Objective: Finasteride reduces prostate cancer risk by blocking the conversion of testosterone to dihydrotestosterone. However, whether finasteride affects estrogens levels or change in estrogens affects prostate cancer risk is unknown. Methods: These questions were investigated in a case-control study nested within the prostate cancer prevention trial (PCPT) with 1,798 biopsy-proven prostate cancer cases and 1,798 matched controls. Results: Among men on placebo, no relationship of serum estrogens with risk of prostate cancer was found. Among those on finasteride, those in the highest quartile of baseline estrogen levels had a moderately increased risk of Gleason score<7 prostate cancer (for estrone, odds ratio [OR]=1.51, 95% confidence interval [CI]=1.06-2.15; for estradiol, OR=1.50, 95% CI=1.03-2.18). Finasteride treatment increased serum estrogen concentrations; however, these changes were not associated with prostate cancer risk. Conclusion: Our findings confirm those from previous studies that there are no associations of serum estrogen with prostate cancer risk in untreated men. In addition, finasteride results in a modest increase in serum estrogen levels, which are not related to prostate cancer risk. Whether finasteride is less effective in men with high serum estrogens, or finasteride interacts with estrogen to increase cancer risk, is uncertain and warrants further investigation. The Author(s), 2011 Prostate cancer nationallicence Etiology nationallicence Estrogen nationallicence Estradiol nationallicence Nested case-control study nationallicence Yao Song Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut Till Cathee Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut Kristal Alan Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut Goodman Phyllis Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut Hsing Ann Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MA, USA aut Tangen Catherine Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut Platz Elizabeth Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MA, USA aut Stanczyk Frank Departments of Obstetrics and Gynecology, and Preventive Medicine, University of Southern California, Los Angeles, CA, USA aut Reichardt Juergen School of Pharmacy and Molecular Sciences, James Cook University, Townsville, QLD, Australia aut Tang Li Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut Neuhouser Marian Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut Santella Regina Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY, USA aut Figg William Medical Oncology Branch and Affiliates, National Cancer Institute, Bethesda, MA, USA aut Price Douglas Medical Oncology Branch and Affiliates, National Cancer Institute, Bethesda, MA, USA aut Parnes Howard Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MA, USA aut Lippman Scott Department of Thoracic Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA aut Thompson Ian Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA aut Ambrosone Christine Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut Hoque Ashraful Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, 1155 Herman P. Pressler, CPB6.3494, Unit 1360, 77030-3721, Houston, TX, USA aut Cancer Causes & Control Springer Netherlands 22/8(2011-08-01), 1121-1131 0957-5243 22:8<1121 2011 22 10552 https://doi.org/10.1007/s10552-011-9787-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10552-011-9787-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Yao Song Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Till Cathee Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut NATIONALLICENCE 700 1- Kristal Alan Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut NATIONALLICENCE 700 1- Goodman Phyllis Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut NATIONALLICENCE 700 1- Hsing Ann Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MA, USA aut NATIONALLICENCE 700 1- Tangen Catherine Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut NATIONALLICENCE 700 1- Platz Elizabeth Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MA, USA aut NATIONALLICENCE 700 1- Stanczyk Frank Departments of Obstetrics and Gynecology, and Preventive Medicine, University of Southern California, Los Angeles, CA, USA aut NATIONALLICENCE 700 1- Reichardt Juergen School of Pharmacy and Molecular Sciences, James Cook University, Townsville, QLD, Australia aut NATIONALLICENCE 700 1- Tang Li Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Neuhouser Marian Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA aut NATIONALLICENCE 700 1- Santella Regina Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY, USA aut NATIONALLICENCE 700 1- Figg William Medical Oncology Branch and Affiliates, National Cancer Institute, Bethesda, MA, USA aut NATIONALLICENCE 700 1- Price Douglas Medical Oncology Branch and Affiliates, National Cancer Institute, Bethesda, MA, USA aut NATIONALLICENCE 700 1- Parnes Howard Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MA, USA aut NATIONALLICENCE 700 1- Lippman Scott Department of Thoracic Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA aut NATIONALLICENCE 700 1- Thompson Ian Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA aut NATIONALLICENCE 700 1- Ambrosone Christine Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA aut NATIONALLICENCE 700 1- Hoque Ashraful Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, 1155 Herman P. Pressler, CPB6.3494, Unit 1360, 77030-3721, Houston, TX, USA aut NATIONALLICENCE 773 0- Cancer Causes & Control Springer Netherlands 22/8(2011-08-01), 1121-1131 0957-5243 22:8<1121 2011 22 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer